- Home
- PETS vs MIST Comparison
PETS vs MIST Comparison
Compare PETS & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PETS
- MIST
- Stock Information
- Founded
- PETS 1996
- MIST 2003
- Country
- PETS United States
- MIST Canada
- Employees
- PETS N/A
- MIST N/A
- Industry
- PETS Retail-Drug Stores and Proprietary Stores
- MIST Biotechnology: Pharmaceutical Preparations
- Sector
- PETS Consumer Staples
- MIST Health Care
- Exchange
- PETS Nasdaq
- MIST Nasdaq
- Market Cap
- PETS 82.0M
- MIST 81.5M
- IPO Year
- PETS N/A
- MIST N/A
- Fundamental
- Price
- PETS $4.07
- MIST $1.43
- Analyst Decision
- PETS Sell
- MIST Strong Buy
- Analyst Count
- PETS 2
- MIST 3
- Target Price
- PETS $3.50
- MIST $13.00
- AVG Volume (30 Days)
- PETS 182.6K
- MIST 177.8K
- Earning Date
- PETS 11-06-2024
- MIST 11-11-2024
- Dividend Yield
- PETS 29.41%
- MIST N/A
- EPS Growth
- PETS N/A
- MIST N/A
- EPS
- PETS N/A
- MIST N/A
- Revenue
- PETS $270,772,000.00
- MIST N/A
- Revenue This Year
- PETS N/A
- MIST N/A
- Revenue Next Year
- PETS $3.27
- MIST N/A
- P/E Ratio
- PETS N/A
- MIST N/A
- Revenue Growth
- PETS 2.26
- MIST N/A
- 52 Week Low
- PETS $2.90
- MIST $1.12
- 52 Week High
- PETS $8.27
- MIST $3.52
- Technical
- Relative Strength Index (RSI)
- PETS 56.76
- MIST 42.50
- Support Level
- PETS $3.78
- MIST $1.41
- Resistance Level
- PETS $4.17
- MIST $1.53
- Average True Range (ATR)
- PETS 0.18
- MIST 0.07
- MACD
- PETS -0.01
- MIST -0.01
- Stochastic Oscillator
- PETS 62.22
- MIST 26.96
About PETS PetMed Express Inc.
PetMed Express Inc along with its subsidiaries is a nationwide pet pharmacy. The company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats, direct to the consumer. The company generates its revenue by selling pet medications and pet supplies mainly to retail consumers.
About MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to terminate episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).